In Corporate Livewire‘s June 2013 Round Table “Biotech & Pharmaceutical,” Dr. Gregory Bell and other leading experts discuss changes and analyze the effects they will have in the industry.
Pricing implications for drugs included in China’s Rare Diseases Catalogue (RDC)
China’s Rare Disease Catalogue (RDC) plays a growing role in shaping awareness, investment, and access to therapies for rare diseases in China.